Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) — Cash Flow Reinvestment Rate
Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) has a Cash Flow Reinvestment Rate of 0.06x as of September 2025, reinvesting CN¥4.69 Million (capex CN¥4.69 Million ) from operating cash flow of CN¥76.07 Million. Explore Beijing Sun Novo Pharmaceutical Research capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Beijing Sun Novo Pharmaceutical Research Co Ltd Cash Flow Reinvestment Rate (2017–2024)
Historical reinvestment intensity for Beijing Sun Novo Pharmaceutical Research Co Ltd across 8 annual periods. Also explore total assets of Beijing Sun Novo Pharmaceutical Research for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Beijing Sun Novo Pharmaceutical Research Co Ltd (2017–2024)
Year-by-year capital reinvestment analysis for Beijing Sun Novo Pharmaceutical Research Co Ltd. For live market cap and broader valuation context, see market value of Beijing Sun Novo Pharmaceutical Research.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 2.11x | CN¥67.63 Million | CN¥32.02 Million | CN¥30.48 Million | ▲ +21.4% |
| 2023 | 1.74x | CN¥161.62 Million | CN¥92.86 Million | CN¥72.96 Million | ▲ +56.8% |
| 2022 | 1.11x | CN¥115.37 Million | CN¥103.96 Million | CN¥103.87 Million | ▼ -72.9% |
| 2021 | 4.09x | CN¥360.74 Million | CN¥88.25 Million | CN¥84.96 Million | ▲ +310.5% |
| 2020 | 1.00x | CN¥62.74 Million | CN¥62.99 Million | CN¥27.03 Million | ▲ +39.0% |
| 2019 | 0.72x | CN¥40.83 Million | CN¥56.97 Million | CN¥25.67 Million | ▲ +92.6% |
| 2018 | 0.37x | CN¥16.41 Million | CN¥44.11 Million | CN¥16.41 Million | ▼ -85.8% |
| 2017 | 2.62x | CN¥20.96 Million | CN¥8.01 Million | CN¥20.96 Million | — |